Clinical significance of the determination of angiogenic factors

Toi, Masakazu; Taniguchi, Tadaaki; Yamamoto, Yutaka; Kurisaki, Takashi; Suzuki, Hideo; Tominaga, Takeshi

doi:10.1016/s0959-8049(96)00397-8

Cited by 95 publications

(55 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This process depends on tightly controlled endothelial cell proliferation, migration and survival, and it is regulated by numerous molecular processes (8,11,14). Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is a heparin-binding glycoprotein with a selective mitogenic effect on vascular endotherial cells and is the most potent and specific agent among the many angiogenic factors (9,10,(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

“…Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is a heparin-binding glycoprotein with a selective mitogenic effect on vascular endotherial cells and is the most potent and specific agent among the many angiogenic factors (9,10,(12)(13)(14). Activities of VEGF include enhancement of both angiogenesis and vascular permeability (9,10,12,14). VEGF is synthesized and secreted by many types of tumors, and expression levels of VEGF correlate with tumor status and prognosis (14,(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

“…Activities of VEGF include enhancement of both angiogenesis and vascular permeability (9,10,12,14). VEGF is synthesized and secreted by many types of tumors, and expression levels of VEGF correlate with tumor status and prognosis (14,(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

“…Immunohistochemical staining for CD34 is used to evaluate microvessel density (MVD) in numerous tumor tissues, and intratumoral MVD is useful in predicting relapse or metastasis (22)(23)(24). The assessment of VEGF expression significantly correlates with MVD in different types of tumors (14,15,(17)(18)(19)25).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immunohistochemical Analysis of Vascular Endothelial Growth Factor (VEGF) Expression and Tumor Angiogenesis in Tongue Squamous Cell Carcinomas.

et al. 2003

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunohistochemical Analysis of Vascular Endothelial Growth Factor (VEGF) Expression and Tumor Angiogenesis in Tongue Squamous Cell Carcinomas.

et al. 2003

View full text Add to dashboard Cite

“…Until recently, measurement of intratumoral microvessel density by immunocytochemistry appeared to be the most reliable method of assessing angiogenic activity (Toi et al, 1996). An alternative method for evaluating angiogenic activity is the determination of the levels of each angiogenic factor in tumour tissues and serum (Poon et al, 2001).…”

mentioning

confidence: 99%

Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma

et al. 2002

View full text Add to dashboard Cite

It is now clear that angiogenesis and angiogenesis factors are important in the pathogenesis of haematological malignancies. High pretreatment levels of serum basic fibroblast growth factor have been shown to be associated with poor prognosis in patients with non-Hodgkin's lymphoma. The aim of this study was to evaluate whether non-Hodgkin's lymphoma cells express basic fibroblast growth factor and/or its receptor (fibroblast growth factor receptor-1) and whether basic fibroblast growth factor expression correlates with basic fibroblast growth factor serum levels, intratumoral microvessel density, and patient outcome. We measured basic fibroblast growth factor by enzyme-linked immunosorbent assay in sera taken from 58 patients with non-Hodgkin's lymphoma before treatment and in 19 of them also after treatment. Pathological specimens at diagnosis were evaluated by immunohistochemistry staining using polyoclonal antibody against factor-VIII-related antigen, basic fibroblast growth factor and fibroblast growth factor receptor-1 to determine the expression of the microvessel count and basic fibroblast growth factor and fibroblast growth factor receptor-1. The lymphoma specimens demonstrated positive staining for basic fibroblast growth factor (in 23%) and fibroblast growth factor receptor-1 (in 58.5%). The patients who expressed basic fibroblast growth factor had a significantly worse progression-free and overall survival than those who did not (P=0.003 and P=0.03 respectively), while patients expressing fibroblast growth factor receptor-1 were less likely to achieve complete remission than those lacking the receptor (33% vs 65% , P=0.047). There was no correlation of basic fibroblast growth factor staining with either serum basic fibroblast growth factor levels or microvessel count. Basic fibroblast growth factor serum levels did not change significantly after treatment These results suggest that non-Hodgkin's lymphoma specimens express basic fibroblast growth factor and its receptor (fibroblast growth factor receptor-1) and this expression is associated with poor patient outcome.

show abstract